SamMobile has affiliate and sponsored partnerships. If you buy something through one of these links, we may earn a commission. Learn more.

Samsung to trade semiconductor expertise for COVID-19 vaccine patents


Last updated: May 17th, 2021 at 17:19 UTC+02:00

What do semiconductors and COVID-19 vaccines have in common? Nothing really, but Samsung Biologics reportedly wants to secure vaccine production orders as well as patented technologies from US-based pharmaceutical companies Pfizer and Moderna, and the Korean tech giant’s semiconductor expansion plans in the USA might be used as leverage.

President Moon Jae-in will attend the first summit with U.S. President Joe Biden on May 21, and according to the Korean media, the two leaders will discuss possible collaborations for vaccine manufacturing. According to the Korean president’s chief policy secretary Lee Ho-seung, the USA wants to turn South Korea into a global vaccine production hub, seeing how the country is the world’s second-largest in terms of drug manufacturing capacity.

Meanwhile, the same report suggests that Samsung Biologics could become a much more vital piece to the US-South Korea dynamic. While Samsung Biologics is already producing vaccines on a contractual basis, the company reportedly wants to acquire more patents for two reasons: firstly the company aims to win more orders from Pfizer and Moderna, and secondly, the company is looking to expand its supply lines in Asia and Europe.

Samsung to leverage its semiconductor investment plans

There’s no secret that the USA is hoping that Samsung Semiconductor will contribute to the country’s chip manufacturing infrastructure before the end of the year, and Samsung might eventually decide to establish new manufacturing plants on US soil.

This collaboration has yet to be set in stone, and according to recent news, Samsung might end up leveraging the expansion plans of its Semiconductor division as a way to secure more vaccine-related patents for Samsung Biologics.

According to an unnamed government official cited by the Korean media, President Moon is expected to tell Biden what role South Korea can play, through Samsung Electronics, to back the U.S. president’s semiconductor initiatives.

The USA has so far been reluctant to sharing patented biopharmaceutical technologies because they are considered ‘strategic items,’ but the Biden administration could agree on sharing some of those technologies with Samsung Biologics if it means that Samsung’s semiconductor division will continue investing in the US’ semiconductor infrastructure.

General Samsung BiologicsSamsung SemiconductorUSA
Load 2 comments

You might also like

Galaxy S20 FE 5G’s unlocked model gets June 2022 security update …

A couple of weeks ago, the international variants of the Galaxy S20 FE and the Galaxy S20 FE 5G received the J …

  • By Asif Iqbal Shaik
  • 2 hours ago

Samsung to push 3nm chipsets into mass-production next week

Samsung is reportedly days away from announcing that it is ready to mass-manufacture 3nm semiconductors. In tu …

  • By Mihai Matei
  • 1 day ago

Galaxy S20 FE 5G gets June 2022 security update in the US

Samsung released the June 2022 security update to the international model of the Galaxy S20 FE and the Galaxy …

  • By Asif Iqbal Shaik
  • 1 day ago

AT&T’s trade-in deal can get you up to $800 off on high-end …

Most good offers from cellular network carriers are usually limited to new customers. However, AT&T is run …

  • By Asif Iqbal Shaik
  • 2 days ago

Samsung Wallet app is now available for download

Earlier this week, Samsung announced a new service called Samsung Wallet that combines all the features of Sam …

  • By Asif Iqbal Shaik
  • 2 days ago

Galaxy S22’s June 2022 software update in the US brings camera i …

Earlier this month, Samsung had released a new software update to the Galaxy S22 series to improve the camera …

  • By Asif Iqbal Shaik
  • 3 days ago